ÂÜÀòÂÒÂ×

Kevin N. Ramdas, M.D., M.P.H. joined Longeveron in November 2019 to lead the Clinical Trials Division and was an integral leader in closing out their Phase 1 clinical trial and initiating their Phase 2 clinical trials while working with the team to file an IPO. Longeveron was publicly listed on the NASDAQ in February 2021. Dr. Ramdas has over a decade of experience in clinical research and operations. Dr. Ramdas spent the previous six years at the University of Miami’s Miller School of Medicine in the Interdisciplinary Stem Cell Institute as well as the Department of Neurology and Neurosurgery. Dr. Ramdas earned his Bachelor of Science in Psychology and Social Sciences with a Minor in Biological Sciences at Florida State University, his M.D. from the American University of Antigua/Windsor School of Medicine, and his M.P.H. in disease prevention and health promotion from the University of Miami’s Miller School of Medicine.